Key facts
- This page summarizes Arjun Goyal's Form 3 filing for Centessa Pharmaceuticals plc (CNTA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 May 2021, 20:32.
Arjun Goyal - 27 May 2021 Form 3 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Director
- Issuer ticker
- CNTA
- Reported as of
- 27 May 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 27 May 2021, 20:32:36 UTC
- Next SEC filing
- 04 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marella Thorell, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arjun Goyal filed Form 3 for Centessa Pharmaceuticals plc (CNTA) on 27 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNTA
holding
Derivative
Series A Preferred Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 May 2021
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,095,909
- Exercise price
- Footnotes
- F1, F2, F3
CNTA
holding
Derivative
Series A Preferred Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 27 May 2021
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 85,909
- Exercise price
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Immediately prior to the closing of the initial public offering closing, Series A Preferred Shares will automatically convert on a one-to-one basis into Ordinary Shares without payment or further consideration. The resulting number of Ordinary Shares of the Issuer are shown in Column 3. The Series A Preferred Shares have no expiration date.
Footnote F2
Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F3
Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F4
Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
SEC remarks
Exhibit 24 - Power of Attorney